These results suggest that optimizing a Trop2-CD3 bispecific antibody requires careful calibration of safety and efficacy, aiming to achieve tumor-specific cytotoxicity without eliciting excessive T-cell activation. This evidence concerns the gene TACSTD2 and neoplasm.